SEC Form 3 · accession 0001140361-17-025624
CYTRX CORP · CYTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shanta Chawla M.D.
Officer — Senior VP-Drug Development
Period of report
Jun 13, 2017
Accepted (ET)
Jun 20, 2017 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000799698
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| CytRx Common Stock | holding | — | — | — | 2,100 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.48 | holding | — | — | — | — | Oct 16, 2026 | CytRx Common Stock | 120,000 | — | D |
Explanation of responses
- F1The stock option vests monthly for 36 months in equal installments, beginning October 17, 2016, provided Reporting Person remains in continuous employ of Issuer.